Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.

被引：2
|
作者：
O'Brien, Mary E. R.
Eberhardt, Wilfried Ernst Erich
Altorki, Nasser K.
Spigel, David R.
Crino, Lucio
Tsai, Chun-Ming
Cho, Eun Kyung
Kim, Joo-Hang
Szczesna, Aleksandra
Hoffman, Philip C.
Burghuber, Otto
Keshavjee, Shaf
Orlov, Sergey
Serwatowski, Piotr
Wang, Jiuzhou
Foley, Margaret A.
Horan, Julie D.
Park, Jung Wook
Shepherd, Frances A.
Kelly, Karen
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol,Ruhrlandklin, Essen, Germany
[3] New Presbyterian Hosp Weill Cornell Med Coll, New York, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Perugia, I-06100 Perugia, Italy
[6] Taipei Vet Gen Hosp, Dept Chest Med, Div Thorac Oncol, Taipei, Taiwan
[7] Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan
[8] Gachon Univ, Gil Med Ctr, Inchon, South Korea
[9] Yonsei Univ Heath Syst, Yonsei Canc Ctr, Seoul, South Korea
[10] Mazowieckie Ctr Leczenia Chorob Pluc, Otwock, Poland
[11] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[12] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[13] Univ Hlth Network, Princess Margaret Canc Ctr, Div Thorac Surg, Toronto, ON, Canada
[14] St Petersburg Med Univ, St Petersburg, Russia
[15] Specjalisty Szpital, Szczecin, Poland
[16] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[17] Novella Clin, Boulder, CO USA
[18] Astellas Pharma Global Dev, Northbrook, IL USA
[19] Princess Margaret Canc Ctr, Toronto, ON, Canada
[20] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7535
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy
    Otterson, G. A.
    O'Connor, P. G.
    Lin, M.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
    Camidge, D. Ross
    Otterson, Gregory Alan
    Clark, Jeffrey W.
    Ou, Sai-Hong Ignatius
    Weiss, Jared
    Ades, Steven
    Conte, Umberto
    Tang, Yiyun
    Wang, Sherry Chia-E
    Murphy, Danielle
    Wilner, Keith D.
    Villaruz, Liza Cosca
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [24] Cutaneous toxicity in erlotinib treatment for advanced non-small cell lung cancer (NSCLC)
    Bernabee, R.
    Cobo, M.
    Barneto, I.
    Valdivia, J.
    Fernandez, I.
    Rueda, A.
    Villatoro, R.
    de la Curz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] ERLOTINIB VERSUS GEFITINIB TREATMENT FOR NON-SMALL CELL LUNG CANCER (NSCLC): A SINGLE INSTITUTION EXPERIENCE IN KOREA
    Lee, S. Y.
    Kim, J. H.
    In, K. H.
    Kim, H. K.
    Kim, S. E.
    Kim, Y. K.
    Yong, H. S.
    Kang, K. H.
    Kang, D. Y.
    Yang, D. S.
    LUNG CANCER, 2009, 64 : S58 - S58
  • [26] Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): The TARZO trial
    Reguart, N.
    Isla, D.
    Cardona, A. F.
    Palmero, R.
    Cardenal, F.
    Rolfo, C.
    Montanes, A.
    Queralt, C.
    Carcereny, E.
    Rosell, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 550 - 550
  • [27] THE ANALYSIS OF INFLUENCE OF CLINICAL PREDICTORS ON THE RESULTS OF TREATMENT WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Salajka, Frantisek
    Pesek, Milos
    Krejci, Jana
    Skrickova, Jana
    Zatloukal, Petr
    Koubkova, Leona
    Grygarkova, Ivona
    Hrnciarik, Michal
    Sticha, Michal
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1293 - S1294
  • [28] Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC)
    Zaric, Bojan
    Stojsic, Vladimir
    Tepavac, Aleksandar
    Sarcev, Tatjana
    Zarogoulidis, Paul
    Darwiche, Kaid
    Tsakiridis, Kosmas
    Karapantzos, Ilias
    Kesisis, Georgios
    Kougioumtzi, Ioanna
    Katsikogiannis, Nikolaos
    Machairiotis, Nikolaos
    Stylianaki, Aikaterini
    Foroulis, Christophoros N.
    Zarogoulidis, Konstantinos
    Perin, Branislav
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S371 - S377
  • [29] Safety of erlotinib in patients with metastatic non-small cell lung cancer (NSCLC) exposed to radiation therapy (RTX)
    Scheffler, M.
    Semrau, R.
    Zander, T.
    Nogova, L.
    Papachristou, I.
    Bos, M.
    Stoelben, E.
    Engel-Riedel, W.
    Wolf, J.
    ONKOLOGIE, 2011, 34 : 153 - 154
  • [30] ERLOTINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CARCINOMA (NSCLC) - A CZECH RETROSPECTIVE ANALYSIS
    Pesek, M.
    Zatloukai, P.
    Skrickova, J.
    Kolek, V.
    Koubkova, L.
    Salajka, F.
    Sixtova, D.
    Zemanova, M.
    Roubec, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 122 - 122
12345